Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Erratum. Hostility, race, and glucose metabolism in nondiabetic individuals. Diabetes Care 2002;25:835-839.

Surwit RS, Williams RB, Siegler IC, Lane JD, Helms M, Applegate KL, Zucker N, Feinglos MN, McCaskill CM, Barefoot JC.

Diabetes Care. 2020 Mar;43(3):691. doi: 10.2337/dc20-er03. Epub 2019 Dec 5. No abstract available.

PMID:
31806650
2.
3.

Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial.

Bress AP, King JB, Kreider KE, Beddhu S, Simmons DL, Cheung AK, Zhang Y, Doumas M, Nord J, Sweeney ME, Taylor AA, Herring C, Kostis WJ, Powell J, Rastogi A, Roumie CL, Wiggers A, Williams JS, Yunis R, Zias A, Evans GW, Greene T, Rocco MV, Cushman WC, Reboussin DM, Feinglos MN, Papademetriou V; SPRINT Research Group.

Diabetes Care. 2017 Aug 9. pii: dc170885. doi: 10.2337/dc17-0885. [Epub ahead of print]

4.

Technosphere insulin: inhaled prandial insulin.

Setji TL, Hong BD, Feinglos MN.

Expert Opin Biol Ther. 2016;16(1):111-7. doi: 10.1517/14712598.2016.1121230. Epub 2015 Dec 11. Review.

PMID:
26567896
5.

Barriers to care for patients with diabetes in Durham, North Carolina, why are we withholding life-sustaining medications from the patients who need them the most?

Spratt SE, Feinglos MN, Willis JM.

Expert Rev Endocrinol Metab. 2015 Sep;10(5):459-461. doi: 10.1586/17446651.2015.1069704. Epub 2015 Jul 27.

PMID:
30298767
6.

The Effect of Blood Glucose Self-Monitoring Among Inmates With Diabetes.

Hunter Buskey RN, Mathieson K, Leafman JS, Feinglos MN.

J Correct Health Care. 2015 Oct;21(4):343-54. doi: 10.1177/1078345815599782. Epub 2015 Aug 14.

PMID:
26276137
7.

Education, glucose control, and mortality risks among U.S. older adults with diabetes.

Dupre ME, Silberberg M, Willis JM, Feinglos MN.

Diabetes Res Clin Pract. 2015 Mar;107(3):392-9. doi: 10.1016/j.diabres.2014.12.013. Epub 2015 Jan 21.

PMID:
25649910
8.

Methods and initial findings from the Durham Diabetes Coalition: Integrating geospatial health technology and community interventions to reduce death and disability.

Spratt SE, Batch BC, Davis LP, Dunham AA, Easterling M, Feinglos MN, Granger BB, Harris G, Lyn MJ, Maxson PJ, Shah BR, Strauss B, Thomas T, Califf RM, Miranda ML.

J Clin Transl Endocrinol. 2015 Jan 14;2(1):26-36. doi: 10.1016/j.jcte.2014.10.006. eCollection 2015 Mar.

9.

HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

Ahrén B, Johnson SL, Stewart M, Cirkel DT, Yang F, Perry C, Feinglos MN; HARMONY 3 Study Group.

Diabetes Care. 2014 Aug;37(8):2141-8. doi: 10.2337/dc14-0024. Epub 2014 Jun 4.

PMID:
24898304
10.

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, Ye J, Scott R, Johnson S, Stewart M, Rosenstock J; HARMONY 7 study group.

Lancet Diabetes Endocrinol. 2014 Apr;2(4):289-97. doi: 10.1016/S2213-8587(13)70214-6. Epub 2014 Feb 6. Erratum in: Lancet Diabetes Endocrinol. 2014 Mar;2(3):e5.

PMID:
24703047
11.

Missing signposts on the roadmap to quality: a call to improve medication adherence indicators in data collection for population research.

Granger BB, Rusincovitch SA, Avery S, Batch BC, Dunham AA, Feinglos MN, Kelly K, Pierre-Louis M, Spratt SE, Califf RM.

Front Pharmacol. 2013 Nov 7;4:139. doi: 10.3389/fphar.2013.00139. eCollection 2013.

12.

A comparison of phenotype definitions for diabetes mellitus.

Richesson RL, Rusincovitch SA, Wixted D, Batch BC, Feinglos MN, Miranda ML, Hammond WE, Califf RM, Spratt SE.

J Am Med Inform Assoc. 2013 Dec;20(e2):e319-26. doi: 10.1136/amiajnl-2013-001952. Epub 2013 Sep 11.

13.

A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection.

Amiram M, Luginbuhl KM, Li X, Feinglos MN, Chilkoti A.

J Control Release. 2013 Nov 28;172(1):144-151. doi: 10.1016/j.jconrel.2013.07.021. Epub 2013 Aug 6.

14.

Two diets with different haemoglobin A1c and antiglycaemic medication effects despite similar weight loss in type 2 diabetes.

Mayer SB, Jeffreys AS, Olsen MK, McDuffie JR, Feinglos MN, Yancy WS Jr.

Diabetes Obes Metab. 2014 Jan;16(1):90-3. doi: 10.1111/dom.12191. Epub 2013 Aug 29.

15.

Risk vs benefit in diabetes pharmacotherapy: a rational approach to choosing pharmacotherapy in type 2 diabetes.

Cox ME, Feinglos MN.

Curr Diab Rep. 2013 Jun;13(3):319-28. doi: 10.1007/s11892-013-0374-z. Review.

PMID:
23512666
16.

Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control.

Amiram M, Luginbuhl KM, Li X, Feinglos MN, Chilkoti A.

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2792-7. doi: 10.1073/pnas.1214518110. Epub 2013 Jan 28.

17.

Pilot Study of Caffeine Abstinence for Control of Chronic Glucose in Type 2 Diabetes.

Lane JD, Lane AJ, Surwit RS, Kuhn CM, Feinglos MN.

J Caffeine Res. 2012 May 24;2(1):45-47. Epub 2012 Apr 26.

18.

Robertsite, Ca(2)Mn(III) (3)O(2)(PO(4))(3)·3H(2)O.

Andrade MB, Morrison SM, Di Domizio AJ, Feinglos MN, Downs RT.

Acta Crystallogr Sect E Struct Rep Online. 2012 Oct 1;68(Pt 10):i74-i75. doi: 10.1107/S160053681203735X. Epub 2012 Sep 15.

19.

Physician reasons for nonpharmacologic treatment of hyperglycemia in older patients newly diagnosed with type 2 diabetes mellitus.

Marrett E, Zhang Q, Kanitscheider C, Davies MJ, Radican L, Feinglos MN.

Diabetes Ther. 2012 Nov;3(1):5. doi: 10.1007/s13300-012-0005-8. Epub 2012 Jun 15.

20.

Receipt of care and reduction of lower extremity amputations in a nationally representative sample of U.S. Elderly.

Sloan FA, Feinglos MN, Grossman DS.

Health Serv Res. 2010 Dec;45(6 Pt 1):1740-62. doi: 10.1111/j.1475-6773.2010.01157.x. Epub 2010 Aug 16.

21.

Plasma epinephrine predicts fasting glucose in centrally obese African-American women.

Surwit RS, Williams RB, Lane JD, Feinglos MN, Kuhn CM, Georgiades A.

Obesity (Silver Spring). 2010 Sep;18(9):1683-7. doi: 10.1038/oby.2010.43. Epub 2010 Mar 18.

22.

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.

Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, Childress RD, Craven TE, Cuddihy RM, Dailey G, Feinglos MN, Ismail-Beigi F, Largay JF, O'Connor PJ, Paul T, Savage PJ, Schubart UK, Sood A, Genuth S; ACCORD Investigators.

BMJ. 2010 Jan 8;340:b5444. doi: 10.1136/bmj.b5444.

23.

Algorithm: management of diabetes mellitus: dietary and drug therapy.

Shill J, Bethel MA, Feinglos MN.

Postgrad Med. 2009 Jul;121(4):170-1. doi: 10.3810/pgm.2009.07.2045. No abstract available.

PMID:
19641284
24.

Algorithm: management of diabetes mellitus.

Shill J, Bethel MA, Feinglos MN.

Postgrad Med. 2009 Jul;121(4):169. doi: 10.3810/pgm.2009.07.2044. No abstract available.

PMID:
19641283
25.

Hostility and minimal model of glucose kinetics in African American women.

Surwit RS, Lane JD, Millington DS, Zhang H, Feinglos MN, Minda S, Merwin R, Kuhn CM, Boston RC, Georgiades A.

Psychosom Med. 2009 Jul;71(6):646-51. doi: 10.1097/PSY.0b013e3181acee4c. Epub 2009 Jun 26.

26.

Hostility and fasting glucose in African American women.

Georgiades A, Lane JD, Boyle SH, Brummett BH, Barefoot JC, Kuhn CM, Feinglos MN, Williams RB, Merwin R, Minda S, Siegler IC, Surwit RS.

Psychosom Med. 2009 Jul;71(6):642-5. doi: 10.1097/PSY.0b013e3181acee3a. Epub 2009 Jun 24.

27.

Offspring of patients with diabetes exhibit a clustering of psychosocial distress and inflammatory and metabolic risk factors.

Shill JE, Feinglos MN, Suarez EC.

Diabetes Care. 2008 Nov;31(11):e86. doi: 10.2337/dc08-1482. No abstract available.

28.

Are you what you eat, or how much you eat? The case of type 2 diabetes mellitus.

Feinglos MN, Totten SE.

Arch Intern Med. 2008 Jul 28;168(14):1485-6. doi: 10.1001/archinte.168.14.1485. No abstract available.

PMID:
18663159
29.

The growing burden of diabetes mellitus in the US elderly population.

Sloan FA, Bethel MA, Ruiz D Jr, Shea AM, Feinglos MN.

Arch Intern Med. 2008 Jan 28;168(2):192-9; discussion 199. doi: 10.1001/archinternmed.2007.35. Erratum in: Arch Intern Med. 2008 Apr;168(8):860. Shea, Alisa H [corrected to Shea, Alisa M].

PMID:
18227367
30.

Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.

Green JB, Feinglos MN.

Curr Diab Rep. 2007 Oct;7(5):369-75. Review.

PMID:
18173970
31.

Caffeine increases ambulatory glucose and postprandial responses in coffee drinkers with type 2 diabetes.

Lane JD, Feinglos MN, Surwit RS.

Diabetes Care. 2008 Feb;31(2):221-2. Epub 2007 Oct 31. No abstract available.

PMID:
17977936
32.

Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, Kirk JK, Hamilton BP, Ismail-Beigi F, Feeney P; ACCORD Study Group.

Am J Cardiol. 2007 Jun 18;99(12A):34i-43i. Epub 2007 Apr 19.

PMID:
17599423
33.

Exaggeration of postprandial hyperglycemia in patients with type 2 diabetes by administration of caffeine in coffee.

Lane JD, Hwang AL, Feinglos MN, Surwit RS.

Endocr Pract. 2007 May-Jun;13(3):239-43.

PMID:
17599854
34.

Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients.

Bethel MA, Sloan FA, Belsky D, Feinglos MN.

Arch Intern Med. 2007 May 14;167(9):921-7.

PMID:
17502533
35.

Adherence to guidelines and its effects on hospitalizations with complications of type 2 diabetes.

Sloan FA, Bethel MA, Lee PP, Brown DS, Feinglos MN.

Rev Diabet Stud. 2004 Spring;1(1):29-38. Epub 2004 May 10.

36.

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group.

Diabetes Care. 2007 Aug;30(8):1979-87. Epub 2007 May 7. Erratum in: Diabetes Care. 2008 Aug;31(8):1713.

PMID:
17485570
37.

Changes in depressive symptoms and glycemic control in diabetes mellitus.

Georgiades A, Zucker N, Friedman KE, Mosunic CJ, Applegate K, Lane JD, Feinglos MN, Surwit RS.

Psychosom Med. 2007 Apr;69(3):235-41. Epub 2007 Apr 9.

PMID:
17420441
38.

Are sulfonylureas passé?

Green JB, Feinglos MN.

Curr Diab Rep. 2006 Nov;6(5):373-7. Review.

PMID:
17076998
39.

Neighborhood characteristics moderate effects of caregiving on glucose functioning.

Brummett BH, Siegler IC, Rohe WM, Barefoot JC, Vitaliano PP, Surwit RS, Feinglos MN, Williams RB.

Psychosom Med. 2005 Sep-Oct;67(5):752-8.

PMID:
16204434
40.

Emerging care for type 2 diabetes: using insulin to reach lower glycemic goals.

Feinglos MN, Bethel MA.

Cleve Clin J Med. 2005 Sep;72(9):791-9. Review.

41.

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.

Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group.

Diabet Med. 2005 Aug;22(8):1016-23.

PMID:
16026367
42.

Optimizing hospital use of intravenous insulin therapy: improved management of hyperglycemia and error reduction with a new nomogram.

Lien LF, Spratt SE, Woods Z, Osborne KK, Feinglos MN.

Endocr Pract. 2005 Jul-Aug;11(4):240-53.

PMID:
16006296
43.

Treatment regimen determines the relationship between depression and glycemic control.

Surwit RS, van Tilburg MA, Parekh PI, Lane JD, Feinglos MN.

Diabetes Res Clin Pract. 2005 Jul;69(1):78-80.

PMID:
15955389
44.

Diabetes-related knowledge, atherosclerotic risk factor control, and outcomes in acute coronary syndromes.

Sánchez CD, Newby LK, McGuire DK, Hasselblad V, Feinglos MN, Ohman EM.

Am J Cardiol. 2005 Jun 1;95(11):1290-4.

PMID:
15904631
45.

Basal insulin therapy in type 2 diabetes.

Bethel MA, Feinglos MN.

J Am Board Fam Pract. 2005 May-Jun;18(3):199-204. Review.

46.
47.

Diabetes on a cardiovascular ward: adherence to current recommendations.

Bethel MA, Alexander J, Lane J, Barkauskas C, Feinglos MN.

South Med J. 2004 Nov;97(11):1031-7.

PMID:
15586590
48.

Plasma glucose responses in recreational divers with insulin-requiring diabetes.

Dear Gde L, Pollock NW, Uguccioni DM, Dovenbarger J, Feinglos MN, Moon RE.

Undersea Hyperb Med. 2004 Fall;31(3):291-301.

PMID:
15568417
49.

The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results.

Reboussin DM, Goff DC Jr, Lipkin EW, Herrington DM, Summerson J, Steffes M, Crouse RJ 3rd, Jovanovic L, Feinglos MN, Probstfield JL, Banerji MA, Pettitt DJ, Williamson J.

Diabet Med. 2004 Oct;21(10):1082-9.

PMID:
15384954
50.

In-hospital management of type 2 diabetes mellitus.

Lien LF, Angelyn Bethel M, Feinglos MN.

Med Clin North Am. 2004 Jul;88(4):1085-105, xii. Review.

PMID:
15308391

Supplemental Content

Loading ...
Support Center